Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 63, Number 2, July 27, 2004
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levin, N.
Right arrow Articles by Siegal, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levin, N.
Right arrow Articles by Siegal, T.
Related Collections
Right arrow All Clinical trials
Right arrow All Oncology
Right arrow Chemotherapy-tumor
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2004;63:354-356
© 2004 American Academy of Neurology
Brief Communications

Chemotherapy as initial treatment in gliomatosis cerebri

Results with temozolomide

Netta Levin, MD, John Moshe Gomori, MD and Tali Siegal, MD

From the Leslie & Michael Gaffin Center for Neuro-Oncology and the Neuro-Imaging Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Address correspondence and reprint requests to Dr. N. Levin, Department of Neurology, Hadassah University Hospital, Jerusalem 91120, Israel; e-mail: imbar_l{at}netvision.net.il

The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known. Eleven radiotherapy-naive patients received a median number of 10 treatment cycles of temozolomide. An objective response was documented in 45%, and the median time to tumor progression was 13 months with a progression-free survival of 55% at 12 months. These results indicate that radiotherapy to extensive brain regions can be deferred until progressive disease is observed.

Received July 23, 2003. Accepted in final form March 26, 2004.

See also pages 204 and 270




This article has been cited by other articles:


Home page
 NeurologyHome page
G. Kaloshi, S. Everhard, F. Laigle-Donadey, Y. Marie, S. Navarro, K. Mokhtari, A. Idbaih, F. Ducray, J. Thillet, K. Hoang-Xuan, et al.
Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri
Neurology, February 19, 2008; 70(8): 590 - 595.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist, February 1, 2006; 11(2): 165 - 180.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Chamberlain
Gliomatosis cerebri: Better definition, better treatment
Neurology, July 27, 2004; 63(2): 204 - 205.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.